Corresponding Author: Silje Watterdal Syversen, MD, PhD, Division of Rheumatology and Research, Diakonhjemmet Hospital, PO Box 23 Vinderen, N-0319 Oslo, Norway (s.w.syversen@gmail.com).
Accepted for Publication: March 4, 2021.
Author Contributions: Drs Syversen and Sexton had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Syversen, Goll, and Jørgensen contributed equally and are co–first authors. Drs Jahnsen, Bolstad, and Haavardsholm contributed equally and are co–last authors.
Concept and design: Syversen, Goll, Jørgensen, Olsen, Torp, Mørk, Kvien, Jahnsen, Bolstad, Haavardsholm.
Acquisition, analysis, or interpretation of data: Syversen, Goll, Sandanger, Sexton, Olsen, Gehin, Warren, Brun, Klaasen, Karlsen, Noraberg, Zettel, Ljoså, Haugen, Njålla, Bruun, Seeberg, Michelsen, Strand, Skorpe, Blomgren, Bragnes, Dotterud, Thune, Ystrøm, Torp, Mielnik, Kvien, Jahnsen, Bolstad, Haavardsholm.
Drafting of the manuscript: Syversen, Goll, Jørgensen, Sexton, Warren, Blomgren, Torp, Kvien, Bolstad.
Critical revision of the manuscript for important intellectual content: Syversen, Goll, Jørgensen, Sandanger, Sexton, Olsen, Gehin, Warren, Brun, Klaasen, Karlsen, Noraberg, Zettel, Ljoså, Haugen, Njålla, Bruun, Seeberg, Michelsen, Strand, Skorpe, Bragnes, Dotterud, Thune, Ystrøm, Torp, Mielnik, Mørk, Kvien, Jahnsen, Bolstad, Haavardsholm.
Statistical analysis: Syversen, Sexton, Olsen, Brun, Torp, Kvien, Haavardsholm.
Obtained funding: Syversen, Goll, Jørgensen, Torp, Kvien, Bolstad, Haavardsholm.
Administrative, technical, or material support: Syversen, Goll, Sandanger, Sexton, Gehin, Warren, Brun, Klaasen, Noraberg, Zettel, Ljoså, Haugen, Njålla, Bruun, Seeberg, Michelsen, Strand, Skorpe, Bragnes, Dotterud, Thune, Torp, Jahnsen, Bolstad, Haavardsholm.
Supervision: Syversen, Goll, Jørgensen, Michelsen, Ystrøm, Torp, Mørk, Kvien, Jahnsen, Haavardsholm.
Conflict of Interest Disclosures: Dr Syversen reported receipt of personal fees from Thermo Fisher. Dr Goll reported receipt of personal fees from Pfizer, AbbVie, Boehringer Ingelheim, Roche, Orion Pharma, Sandoz, and Novartis. Dr Jørgensen reported receipt of personal fees from Celltrion, AOP Orphan Pharmaceuticals, and Norgine. Dr Gehin reported receipt of personal fees from Roche. Dr Michelsen reported receipt of personal fees from Novartis and grants from Novartis (paid to employer). Dr Dotterud reported receipt of personal fees from LEO Pharma. Dr Mørk reported receipt of personal fees from Novartis Norge, LEO Pharma, ACO Hud Norge, Celgene, AbbVie, Galderma Nordic, and UCB. Dr Kvien reported receipt of grants from AbbVie, Bristol-Myers Squibb, Merck Sharp & Dohme, Pfizer, and UCB and personal fees from AbbVie, Merck Sharp & Dohme, Hospira/Pfizer, Roche, UCB, Lilly, Hikma, Orion, Sanofi, Celltrion, Sandoz, Biogen, Amgen, Egis, Ewopharma, Mylan, EVA Pharma, and Gilead. Dr Bolstad reported receipt of personal fees from Roche, Janssen, and Novartis. Dr Haavardsholm reported receipt of personal fees from Pfizer, AbbVie, Celgene, Novartis, Janssen, Gilead, Lilly, and UCB. No other disclosures were reported.
Funding/Support: The study was funded by grants from the Norwegian Regional Health Authorities (interregional KLINBEFORSK grants) and the South-Eastern Norway Regional Health Authorities. The sponsor of the study was Diakonhjemmet Hospital.
Role of the Funder/Sponsor: Neither the funder of the study (the Regional Health Authorities) nor the sponsor (Diakonhjemmet Hospital) had any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. Neither the funder nor the sponsor had any right to veto publication or to control the decision regarding to which journal the manuscript was submitted. All drafts of the manuscript were prepared by the authors. All authors approved the final submitted version.
Data Sharing Statement: See Supplement 3.
Additional Contributions: We acknowledge the patient representatives, Jon Hagfors (Norwegian Rheumatism Association), Bjørn Gulbrandsen (Norwegian IBD Patient Organization), and Hilde Mellum (Psoriasis and Eczema Association of Norway), for their contributions during planning and conduct of the study. We acknowledge the members of the scientific advisory board, Josef Smolen, MD, PhD (University of Vienna), Alejandro C. Balsa, MD, PhD (University Hospital La Paz, Madrid), Geert D’Haens, MD, PhD (Amsterdam Academic Medical Center), Jørn Brynskov, MD, PhD (University of Copenhagen Herlev Hospital), Knut E. A. Lundin, MD, PhD (University of Oslo), and Diamant Thaci, MD, PhD (University of Lubeck). No compensation was received for their contributions to the protocol. We acknowledge Cecilie Moe, Bjørn Solvang, Nina Flatner, Trond Smedsrud, and Marius Eid, Department of Research Support for Clinical Trials at Oslo University Hospital, and Anja Bye, Clinical Research Unit Central Norway, for research support and data management (received compensation for their work).
1.Maini
R , St Clair
EW , Breedveld
F ,
et al; ATTRACT Study Group. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial.
Lancet. 1999;354(9194):1932-1939. doi:
10.1016/S0140-6736(99)05246-0
PubMedGoogle ScholarCrossref 5.Thomas
SS , Borazan
N , Barroso
N ,
et al. Comparative immunogenicity of TNF inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune diseases. a systematic review and meta-analysis.
BioDrugs. 2015;29(4):241-258. doi:
10.1007/s40259-015-0134-5PubMedGoogle ScholarCrossref 6.Nencini
F , Vultaggio
A , Pratesi
S ,
et al. The kinetics of antidrug antibodies, drug levels, and clinical outcomes in infliximab-exposed patients with immune-mediated disorders.
J Allergy Clin Immunol Pract. 2018;6(6):2065-2072. doi:
10.1016/j.jaip.2018.04.007PubMedGoogle ScholarCrossref 7.St Clair
EW , Wagner
CL , Fasanmade
AA ,
et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial.
Arthritis Rheum. 2002;46(6):1451-1459. doi:
10.1002/art.10302PubMedGoogle ScholarCrossref 13.Grossberg
LB , Papamichael
K , Feuerstein
JD , Siegel
CA , Ullman
TA , Cheifetz
AS . A survey study of gastroenterologists’ attitudes and barriers toward therapeutic drug monitoring of anti-TNF therapy in inflammatory bowel disease.
Inflamm Bowel Dis. 2017;24(1):191-197. doi:
10.1093/ibd/izx023PubMedGoogle ScholarCrossref 15.Vande Casteele
N , Herfarth
H , Katz
J , Falck-Ytter
Y , Singh
S . American Gastroenterological Association Institute technical review on the role of therapeutic drug monitoring in the management of inflammatory bowel diseases.
Gastroenterology. 2017;153(3):835-857. doi:
10.1053/j.gastro.2017.07.031PubMedGoogle ScholarCrossref 16.Feuerstein
JD , Nguyen
GC , Kupfer
SS , Falck-Ytter
Y , Singh
S ; American Gastroenterological Association Institute Clinical Guidelines Committee. American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease.
Gastroenterology. 2017;153(3):827-834. doi:
10.1053/j.gastro.2017.07.032PubMedGoogle ScholarCrossref 17.Ricciuto
A , Dhaliwal
J , Walters
TD , Griffiths
AM , Church
PC . Clinical outcomes with therapeutic drug monitoring in inflammatory bowel disease: a systematic review with meta-analysis.
J Crohns Colitis. 2018;12(11):1302-1315. doi:
10.1093/ecco-jcc/jjy109PubMedGoogle ScholarCrossref 19.Syversen
SW , Goll
GL , Jørgensen
KK ,
et al. Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study).
Trials. 2020;21(1):13. doi:
10.1186/s13063-019-3734-4PubMedGoogle ScholarCrossref 20.Prevoo
ML , van ’t Hof
MA , Kuper
HH , van Leeuwen
MA , van de Putte
LB , van Riel
PL . Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.
Arthritis Rheum. 1995;38(1):44-48. doi:
10.1002/art.1780380107PubMedGoogle ScholarCrossref 21.England
BR , Tiong
BK , Bergman
MJ ,
et al. 2019 update of the American College of Rheumatology recommended rheumatoid arthritis disease activity measures.
Arthritis Care Res (Hoboken). 2019;71(12):1540-1555. doi:
10.1002/acr.24042PubMedGoogle ScholarCrossref 22.Lukas
C , Landewé
R , Sieper
J ,
et al; Assessment of Spondyloarthritis International Society. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis.
Ann Rheum Dis. 2009;68(1):18-24. doi:
10.1136/ard.2008.094870PubMedGoogle ScholarCrossref 23.Machado
P , Landewé
R , Lie
E ,
et al; Assessment of Spondyloarthritis International Society. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores.
Ann Rheum Dis. 2011;70(1):47-53. doi:
10.1136/ard.2010.138594PubMedGoogle ScholarCrossref 24.Lewis
JD , Chuai
S , Nessel
L , Lichtenstein
GR , Aberra
FN , Ellenberg
JH . Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis.
Inflamm Bowel Dis. 2008;14(12):1660-1666. doi:
10.1002/ibd.20520PubMedGoogle ScholarCrossref 26.Vermeire
S , Schreiber
S , Sandborn
WJ , Dubois
C , Rutgeerts
P . Correlation between the Crohn’s disease activity and Harvey-Bradshaw indices in assessing Crohn’s disease severity.
Clin Gastroenterol Hepatol. 2010;8(4):357-363. doi:
10.1016/j.cgh.2010.01.001PubMedGoogle ScholarCrossref 28.Jørgensen
KK , Olsen
IC , Goll
GL ,
et al; NOR-SWITCH Study Group. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.
Lancet. 2017;389(10086):2304-2316. doi:
10.1016/S0140-6736(17)30068-5PubMedGoogle ScholarCrossref 30.Berth-Jones
J , Grotzinger
K , Rainville
C ,
et al. A study examining inter- and intrarater reliability of three scales for measuring severity of psoriasis: Psoriasis Area and Severity Index, Physician’s Global Assessment and Lattice System Physician’s Global Assessment.
Br J Dermatol. 2006;155(4):707-713. doi:
10.1111/j.1365-2133.2006.07389.xPubMedGoogle ScholarCrossref 31.Yoo
DH , Hrycaj
P , Miranda
P ,
et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study.
Ann Rheum Dis. 2013;72(10):1613-1620. doi:
10.1136/annrheumdis-2012-203090PubMedGoogle ScholarCrossref 32.D’Haens
G , Vermeire
S , Lambrecht
G ,
et al; GETAID. Increasing infliximab dose based on symptoms, biomarkers, and serum drug concentrations does not increase clinical, endoscopic, and corticosteroid-free remission in patients with active luminal Crohn’s disease.
Gastroenterology. 2018;154(5):1343-1351. doi:
10.1053/j.gastro.2018.01.004PubMedGoogle ScholarCrossref 35.Kobayashi
T , Suzuki
Y , Motoya
S ,
et al. First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post hoc analysis.
J Gastroenterol. 2016;51(3):241-251. doi:
10.1007/s00535-015-1102-zPubMedGoogle ScholarCrossref 36.Cornillie
F , Hanauer
SB , Diamond
RH ,
et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial.
Gut. 2014;63(11):1721-1727. doi:
10.1136/gutjnl-2012-304094PubMedGoogle ScholarCrossref 37.Papamichael
K , Van Stappen
T , Vande Casteele
N ,
et al. Infliximab concentration thresholds during induction therapy are associated with short-term mucosal healing in patients with ulcerative colitis.
Clin Gastroenterol Hepatol. 2016;14(4):543-549. doi:
10.1016/j.cgh.2015.11.014PubMedGoogle ScholarCrossref 38.Verstockt
B , Moors
G , Bian
S ,
et al. Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn’s disease patients: the usefulness of rapid testing.
Aliment Pharmacol Ther. 2018;48(7):731-739. doi:
10.1111/apt.14943PubMedGoogle ScholarCrossref 39.Kennedy
NA , Heap
GA , Green
HD ,
et al; UK Inflammatory Bowel Disease Pharmacogenetics Study Group. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn’s disease: a prospective, multicentre, cohort study.
Lancet Gastroenterol Hepatol. 2019;4(5):341-353. doi:
10.1016/S2468-1253(19)30012-3PubMedGoogle ScholarCrossref 41.Steenholdt
C , Bendtzen
K , Brynskov
J , Thomsen
OØ , Ainsworth
MA . Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn’s disease: post hoc analysis of a randomized controlled trial.
Am J Gastroenterol. 2014;109(7):1055-1064. doi:
10.1038/ajg.2014.106PubMedGoogle ScholarCrossref